ProShare Advisors
FHTX icon

ProShare Advisors’s Foghorn Therapeutics FHTX Stock Holding History

ProShare Advisors’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,228
Closed -$74.5K – 2056
2025
Q3 		$74.5K Buy
+15,228
New +$80.7K ﹤0.01% 1885

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

ProShare Advisors's FHTX Position: Q4 2025 in Review

ProShare Advisors sold out of Foghorn Therapeutics (FHTX) in Q4 2025, closing a stake of 15,228 shares — an estimated $74.5K sold.

ProShare Advisors first reported a position in FHTX in Q3 2025 and held it in 1 quarter. The position peaked at $74.5K in Q3 2025. 93 funds tracked by Wall St. Rank hold FHTX as of Q4 2025.

  • ProShare Advisors reported no remaining Foghorn Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ProShare Advisors sold 15,228 Foghorn Therapeutics shares in Q4 2025, an estimated $74.5K.
  • ProShare Advisors first reported a position in Foghorn Therapeutics in Q3 2025 and held it in 1 quarter.
  • ProShare Advisors's Foghorn Therapeutics position peaked at $74.5K in Q3 2025.
  • 93 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q4 2025.

Based on ProShare Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.